This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (96)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Alzheimer Disease  • Women's Health  • Menopause  • Alert me on articles by topic  Social Bookmarking   What's this?

A Critical Time

Susan M. Resnick, PhD; Victor W. Henderson, MD, MS

JAMA. 2002;288:2170-2172.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Interest in the effects of hormone therapy on health outcomes among postmenopausal women has perhaps never been greater. As recently reported,¹ the Women's Health Initiative (WHI) randomized clinical trial of postmenopausal hormone therapy terminated the combined estrogen-progestin arm (but not the estrogen-only arm) early after an average follow-up of 5.2 years (planned duration, 8.5 years).² Women who received estrogen plus progestin experienced a small but significant increase in the primary outcome, coronary heart disease; a nonsignificant trend toward an increase in the primary adverse outcome, invasive breast cancer; and a significant increase in a global index (which included the 2 primary outcomes plus stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, and death due to other causes) summarizing risk and benefit. However, the decision to stop this portion of the trial did not take into account several other important outcomes . . . [Full Text of this Article]

Author Affiliations: Laboratory of Personality and Cognition, National Institute on Aging, Baltimore, Md (Dr Resnick), and Departments of Geriatrics, Neurology, Pharmacology & Toxicology, and Epidemiology, University of Arkansas for Medical Sciences, Little Rock (Dr Henderson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Estrogen Replacement and Risk of Alzheimer Disease
Mark A. Smith, George Perry, Craig S. Atwood, and Richard L. Bowen
JAMA. 2003;289(9):1100.
EXTRACT | FULL TEXT  

Estrogen Replacement and Risk of Alzheimer Disease
Lynn Rosenberg
JAMA. 2003;289(9):1101.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women: The Cache County Study
Peter P. Zandi, Michelle C. Carlson, Brenda L. Plassman, Kathleen A. Welsh-Bohmer, Lawrence S. Mayer, David C. Steffens, John C. S. Breitner, and for the Cache County Memory Study Investigators
JAMA. 2002;288(17):2123-2129.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Menopause, cognitive ageing and dementia: practice implications
Henderson
Menopause Int 2009;15:41-44.
ABSTRACT | FULL TEXT  

Neuroprotective effects of the Alzheimer's disease-related gene seladin-1
Peri and Serio
J Mol Endocrinol 2008;41:251-261.
ABSTRACT | FULL TEXT  

Seladin-1 Is a Fundamental Mediator of the Neuroprotective Effects of Estrogen in Human Neuroblast Long-Term Cell Cultures
Luciani et al.
Endocrinology 2008;149:4256-4266.
ABSTRACT | FULL TEXT  

Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause
Rocca et al.
Neurology 2007;69:1074-1083.
ABSTRACT | FULL TEXT  

Brain Infusion of Lipopolysaccharide Increases Uterine Growth as a Function of Estrogen Replacement Regimen: Suppression of Uterine Estrogen Receptor-{alpha} by Constant, But Not Pulsed, Estrogen Replacement
Marriott et al.
Endocrinology 2007;148:232-240.
ABSTRACT | FULL TEXT  

Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women
Morrison et al.
J. Neurosci. 2006;26:10332-10348.
FULL TEXT  

Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies
Turgeon et al.
Endocr. Rev. 2006;27:575-605.
ABSTRACT | FULL TEXT  

Estrogen and Selective Estrogen Receptor Modulators Exert Neuroprotective Effects and Stimulate the Expression of Selective Alzheimer's Disease Indicator-1, a Recently Discovered Antiapoptotic Gene, in Human Neuroblast Long-Term Cell Cultures
Benvenuti et al.
J. Clin. Endocrinol. Metab. 2005;90:1775-1782.
ABSTRACT | FULL TEXT  

Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age
Henderson et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:103-105.
ABSTRACT | FULL TEXT  

Hormone Therapy: Making Decisions in the Face of Uncertainty
Peterson et al.
Arch Intern Med 2004;164:2308-2312.
FULL TEXT  

Estrogen and Dementia: Insights From the Women's Health Initiative Memory Study
Schneider
JAMA 2004;291:3005-3007.
FULL TEXT  

Effects of Testosterone on Behavior, Depression, and Cognitive Function in Older Men With Mild Cognitive Loss
Kenny et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2004;59:M75-78.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Therapy and Its Association With Cognitive Impairment
Mitchell et al.
Arch Intern Med 2003;163:2485-2490.
ABSTRACT | FULL TEXT  

Detangling Alzheimer's Disease
Helmuth
Sci Aging Knowl Environ 2003;2003:oa2-2.
ABSTRACT | FULL TEXT  

Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial
Shumaker et al.
JAMA 2003;289:2651-2662.
ABSTRACT | FULL TEXT  

Estrogen Replacement and Risk of Alzheimer Disease
Smith et al.
JAMA 2003;289:1100-1100.
FULL TEXT  

Estrogen Replacement and Risk of Alzheimer Disease
Rosenberg
JAMA 2003;289:1101-1101.
FULL TEXT  

Hormone Therapy Associated with Lower Incidence of Alzheimer's Disease
JWatch Women's Health 2002;2002:4-4.
FULL TEXT